Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2015 Fourth Quarter And Full Year Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2015 Fourth Quarter And Full Year Financial Results

Sanofi Collaboration Drives Lexicon Pharma's (LXRX) 4Q Success; Wedbush Raises Price Target to $28

March 2, 2016 7:30 AM EST

Wedbush reiterated an Outperform rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), and raised the price target to $28.00 (from $26.00), following the company's 4Q earnings report. Revenues of $127.2MM came in above consensus estimates of $0.3MM. The beat comes due to revenues recognized from the collaboration agreement with... More

Lexicon Pharma (LXRX) Reports Q4 EPS of $0.76

March 1, 2016 7:11 AM EST

Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.76, versus ($0.03) reported last year. Revenue for the quarter came in at $127.3 million, versus $21.5 million reported last year.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

... More